Siftr Bio is a biotechnology company developing precision oncology therapies, with a focus on improving antibody-drug conjugates (ADCs) for hard-to-treat cancers. Its work centres on creating next-generation ADC linkers, the chemical components that help deliver cancer-killing payloads accurately to tumour cells. Through its SIFTR platform, the company combines high-throughput linker development with testing in human patient tumour tissue, aiming to design treatments that are more effective and cause fewer side effects.
This is a company profile stub. Create an account to claim your profile.
Industry
BiotechnologyAreas of Focus
Status
Active
